Abvc Biopharma (ABVC) Current Deferred Revenue (2022 - 2026)

Abvc Biopharma (ABVC) has reported Current Deferred Revenue for 5 consecutive years, with $12600.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue fell 84.47% year-over-year to $12600.0; the trailing twelve-month figure through Jun 2026 stood at $12600.0 (down 84.47% YoY), and the FY2025 full-year result was $12600.0, down 84.47% from the prior year.
• Current Deferred Revenue steadied at $12600.0 in Q2 2026 per ABVC's latest filing, from $12600.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $81115.0 in Q4 2024 and bottomed at $10985.0 in Q4 2022.
• Historically, Current Deferred Revenue has averaged $60731.9 across 5 years, with a median of $79500.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue surged 623.71% in 2023, then slumped 84.47% in 2025.
• Over 5 years, Current Deferred Revenue stood at $10985.0 in 2022, then soared by 623.71% to $79500.0 in 2023, then gained by 2.03% to $81115.0 in 2024, then plunged by 84.47% to $12600.0 in 2025, then changed by 0.0% to $12600.0 in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $12600.0, $12600.0, and $12600.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.